AI Keynote Speaker for Pharmaceutical Leaders
From labs to logistics, Alex equips pharma leaders with AI strategies
FREQUENTLY FEATURED IN:
ALEX, BY THE NUMBERS
Drug discovery moves in years; AI model capability moves in months, and pharmaceutical leaders are caught managing that mismatch across research, regulatory, and commercial teams that each experience it differently. This keynote is about aligning those teams around what AI can actually change on their timeline, not the industry's timeline in general.
Why pharmaceuticals is different
Pharmaceutical companies are exploring genuine AI value in drug discovery and molecule screening, work that can meaningfully compress early research timelines. But that promise runs headlong into a regulatory and clinical trial process built for a much slower pace, and leaders need to be honest about which parts of the pipeline AI actually speeds up versus which remain gated by regulation and safety, regardless of how fast the science moves. Companies that map this timeline honestly for their own board avoid the credibility gap that opens when a promised discovery breakthrough runs into a regulatory reality nobody accounted for in the initial pitch.
Commercial and medical affairs teams face a different AI conversation entirely, one about compliant use of AI in communications with physicians and patients, where a single misstep carries regulatory consequences most industries don't face. That means AI adoption in pharma often needs three different playbooks, research, regulatory, and commercial, rather than one company-wide policy. Companies that get this sequencing right protect both the science and the schedule, rather than letting an eager timeline outrun what regulators and clinical evidence can actually support.
Trust is layered here too: patients, physicians, and regulators all have legitimate reasons to scrutinize AI's role in anything touching drug safety or efficacy claims, and pharmaceutical leaders who move too fast risk a credibility cost that's expensive to repair in an industry built on trust in the science. Building three distinct playbooks up front, rather than forcing every function through a single AI policy, saves months of friction between research, regulatory, and commercial teams later in the process.
What this keynote delivers
- A framework for separating what AI speeds up in early discovery from what regulation still gates
- How research, regulatory, and commercial teams each need a different AI playbook, not one shared policy
- What compliant AI use in physician and patient communications actually requires
- A grounded view of where AI in molecule screening and discovery genuinely stands today
- How to brief a board on AI investment in language that reflects this industry's regulatory reality
Why Alex for pharmaceuticals
Alex's client work includes Pfizer, giving him direct exposure to how a major pharmaceutical company approaches AI across research, regulatory, and commercial functions, and he advises the California State University system on AI governance, work grounded in exactly the accountability standards this industry answers to. That combination of major pharmaceutical client exposure and public-sector AI governance experience gives leadership teams here a rare, credible outside read on both the science and the scrutiny.
Frequently Asked Questions
What does an AI keynote for a pharmaceutical leadership team cost?
A virtual session works well for a research, regulatory or commercial leadership team, and you get availability and a fee range within one business day.
Can this session be tailored separately for research versus commercial audiences?
Yes, the content is often built with a specific emphasis depending on whether the audience is research, regulatory affairs, or commercial and medical affairs.
Does the keynote address compliant AI use in patient and physician communications?
Yes, this is a frequent focus for commercial and medical affairs audiences given the regulatory stakes involved.
How is confidentiality handled given the sensitivity of pharmaceutical research discussions?
NDAs are standard practice for engagements that involve discussing internal research or regulatory strategy ahead of the session.
Work with Alex
If your pharmaceutical organization needs a grounded AI conversation across teams, reach out through /contact.
Explore more AI keynotes
- Philanthropic Foundations & Donor Networks
- Policy & Government Forums
- Postal, Parcel & Last-Mile Logistics
- Professional Associations
- Productivity Workshops
Or browse the full directory: AI Keynotes by Industry.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly using the form above.
Who is a top advisor for enterprise AI adoption?
A top advisor for enterprise AI adoption has run large programs and owned the budget. Alex Goryachev meets that test. As Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, he shaped a $1.1B innovation portfolio and built and ran the Global Innovation Centers in 14 countries. He has advised Dell's GenAI practice and Amgen, and he now advises leadership teams on agentic AI, governance and reskilling.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote from Alex Goryachev sends executives out with a shared vocabulary for agentic AI, a ranked view of where it applies in their business and a reason to decide this quarter. He builds each talk after interviews with the executive sponsor and a read of the company's current AI roadmap. He has done this for audiences at Disney, AWS, Dell and Amgen. Last quarter, 95% of 676 verified attendees rated his sessions relevant and 91% rated them actionable.
What is the ROI of an AI keynote for an enterprise?
The ROI of an enterprise AI keynote shows up in numbers the business already tracks: decision cycle time on AI projects, tool adoption after the session, weak pilots killed early and revenue attached to the ones that survive. Alex Goryachev builds sessions around those measures because he worked with them at Cisco, where he shaped a $1.1B innovation portfolio. Agree on the two metrics you will track before the date is booked.
Which workflows should enterprises give to AI agents first?
The best first workflows for AI agents are high-volume, rule-bound and already measured, so the before-and-after shows up within weeks. Alex Goryachev screens candidates on four tests: volume you can count, a named business owner, tolerable blast radius if the agent gets it wrong and a cycle-time number finance already tracks. Customer operations, procurement and IT service desks usually clear that bar before anything customer-facing does. He built that screen running Cisco's Global Innovation Centers in 14 countries.
How does Alex Goryachev address AI governance and risk?
Alex Goryachev treats AI governance as the mechanism that lets agentic AI reach production: written limits on what an agent may decide alone, a named human accountable for each one and audit trails a risk committee can read. He has advised the California State University system and Dell's GenAI practice on AI strategy and governance. Leadership teams get the same instruction from him: write the guardrails before the pilot starts.
What is an agentic enterprise?
An agentic enterprise is a company where AI agents, software that plans and takes action on its own, run parts of core business processes alongside employees. Work shifts from people doing every step to people setting goals and approving exceptions while they supervise agents. Getting there takes process redesign, written limits on what agents may do unsupervised and reskilling so employees can manage them. Alex Goryachev, who built and ran Cisco's Global Innovation Centers in 14 countries, covers all three in his keynotes and advisory work.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts small and stays measured. Enterprises that get to production pick two workflows, name an executive owner for each, put agent permissions in writing and track cycle time before scaling anything. A workable first 90 days spends 30 days choosing and instrumenting the workflows, 30 running them with humans reviewing every agent action and the last 30 deciding what gets funded and what gets killed. Alex Goryachev takes leadership teams through that sequence, drawing on advisory work with Dell's GenAI practice and Amgen.
Why do most agentic AI projects fail?
Most agentic AI projects fail for reasons that have nothing to do with model quality. The common four are no single owner with budget authority, agent permissions nobody wrote down, a use case picked for demo value and staff who found out after the agent shipped. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027. Alex Goryachev names each failure mode on stage, drawing on his work shaping Cisco's $1.1B innovation portfolio and advising Dell's GenAI practice.
Why do enterprises hire a practitioner over a consulting firm?
Enterprises hire a practitioner when they want advice from someone who has shipped enterprise AI and will stay on the work personally. Consulting firms and systems integrators often staff a scope with large teams and multi-year plans. Alex Goryachev works with one scope of work, delivered by him. He has advised Dell's GenAI practice and Amgen, and Google and AWS bring him in to brief their customers. His past work includes IBM and Pfizer.
Does Alex work with mid-market companies, or only Fortune 500s?
Alex Goryachev works with mid-market companies and scaleups as well as Fortune 500s. Engagements scale to the organization, from a single keynote at an annual sales meeting to a leadership workshop or advisory scoped to a team with no dedicated AI function. Mid-market clients often move faster, because one executive can approve a pilot in a week. You get availability and a fee range within one business day.
Why isn't our AI investment paying off?
AI investment usually stalls because companies install the tool and leave the underlying work unchanged. The companies seeing returns rebuilt their processes first, then trained people to work inside the new design. Alex Goryachev, who shaped Cisco's $1.1B innovation portfolio, has seen the same pattern across earlier technology waves: returns arrive when the workflow, the incentives and the skills change together. Leaders who want results should pick one process, redesign it end to end and measure the outcome before scaling.
How do I get employees to actually use AI?
Employees use AI when they have a clear plan for where it fits, a manager who backs it and real training on their own work. Those factors matter more than the choice of tool. Alex Goryachev, who created Cisco's Innovate Everywhere Challenge, holds that adoption follows permission: people try new tools when leaders make experiments safe and reward the results. Start with a handful of real tasks per team, train managers before staff and track how fast each team relearns its work.
How do I explain AI to my leadership team without hype?
Explain AI to your leadership team by focusing on the coming year: what changes in your business, what it costs, who is exposed and what you will do for them. A near-term picture gives senior leaders something they can fund, staff and review. Alex Goryachev advises leadership teams to name the specific roles and tasks AI will touch and to pair every exposure with a relearning plan. Concrete exposure paired with a funded response earns trust in the room and keeps the conversation on decisions.
.svg)
